Study of Antithrombotic Treatment After Intracerebral Haemorrhage-Antiplatelets: A Randomized Trial

医学 抗血栓 脑出血 随机对照试验 临床终点 随机化 不利影响 冲程(发动机) 血小板聚集抑制剂 外科 纤溶剂 临床试验 麻醉 意向治疗分析 内科学 血管疾病 缺血性中风 抗血小板药物 氯吡格雷 终点 自发性脑出血
作者
Helle Eilertsen,Kristin Tveitan Larsen,Elisabeth Forfang,Johanna Pennlert,Eva‐Lotta Glader,Christina Rostrup Kruuse,Per Olov Wester,Hege Ihle‐Hansen,Maria Lizzie Carlsson,Trine Lied-Herland,Jūratė Šaltytė Benth,Håkon Ihle‐Hansen,Yngve Müller Seljeseth,Marie Norsker Folke,Rustam Al‐Shahi Salman,T. B. Wyller,Ole Morten Rønning,Else Charlotte Sandset,on behalf of all STATICH Investigators
出处
期刊:Stroke [Lippincott Williams & Wilkins]
卷期号:57 (8): 2287-2294
标识
DOI:10.1161/strokeaha.125.054990
摘要

BACKGROUND: Patients surviving spontaneous intracerebral hemorrhage (ICH) who have indications for antithrombotic treatment face increased risks of both hemorrhagic and ischemic events. The aim of STATICH (Study of Antithrombotic Treatment After Intracerebral Haemorrhage) was to assess the safety and efficacy of long-term antithrombotic treatment after ICH. METHODS: STATICH Antiplatelets (EudraCT 2014-002636-13; Unique identifier: NCT03186729) was a randomized, multicenter, open, blinded end point parallel-group trial, including adults with an indication for antiplatelet treatment to either start or avoid antiplatelet treatment. The target sample size was 500 participants. Patients were allocated 1:1 by a Web-based randomization system and followed for a minimum of 2 years. Outcome assessments were done by personnel blinded to treatment. Participants were not blinded. The primary safety outcome was recurrent symptomatic ICH. RESULTS: The trial was stopped early due to slow recruitment. Sixty-nine patients were included between August 2018 and December 2022: 34 were randomized to start antiplatelet treatment, and 35 were randomized to avoid antiplatelet treatment. No patients were excluded from analyses. The median age was 75 (Q1-Q3, 66-80) years, and 43 (75%) had previous ischemic stroke or transient ischemic attack. Five patients in the start antiplatelet treatment group (15% [95% CI, 6%-31%]), and 1 in the avoid group (3% [95% CI, 0%-18%]) experienced recurrent ICH, while 3 (9% [95% CI, 3%-24%]) and 7 (20% [95% CI, 10%-37%]), respectively, experienced a major ischemic event. A total of 88 serious adverse events and no suspected unexpected serious adverse reactions were registered. CONCLUSIONS: There were numerically more recurrent ICHs and fewer ischemic events in patients starting antiplatelet treatment after ICH compared with those avoiding antiplatelet treatment. The slow recruitment might be due to clinicians being certain of the best treatment strategy or patients being too frail to participate. STATICH will contribute to a planned collaborative individual patient-data meta-analysis to resolve this dilemma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
DW发布了新的文献求助10
1秒前
DW发布了新的文献求助10
1秒前
bkagyin的应助被Potato采纳,获得30
1秒前
DW发布了新的文献求助10
1秒前
DW发布了新的文献求助10
1秒前
DW发布了新的文献求助30
2秒前
2秒前
久伴完成签到,获得积分10
2秒前
3秒前
3秒前
Nole的应助被瘦瘦靴采纳,获得10
4秒前
共享精神的应助被搞怪的乐荷采纳,获得10
4秒前
lilac发布了新的文献求助10
4秒前
4秒前
swjfly发布了新的文献求助10
4秒前
5秒前
DW发布了新的文献求助10
5秒前
DW发布了新的文献求助10
5秒前
DW发布了新的文献求助10
5秒前
DW发布了新的文献求助10
5秒前
5秒前
XIAOLI完成签到,获得积分10
6秒前
SciGPT的应助被PP采纳,获得30
7秒前
8秒前
励志发SCI发布了新的文献求助20
8秒前
DW发布了新的文献求助10
8秒前
8秒前
DW发布了新的文献求助10
8秒前
DW发布了新的文献求助10
8秒前
9秒前
業業发布了新的文献求助10
10秒前
10秒前
RRR关注了科研通微信公众号
10秒前
Aurora发布了新的文献求助10
10秒前
情怀的应助被daylight采纳,获得10
11秒前
DW发布了新的文献求助10
11秒前
DW发布了新的文献求助10
11秒前
DW发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157